Complete metabolic response following anaplastic lymphoma kinase (ALK) targeted therapy in a patient with adenocarcinoma of unknown primary with immunohistochemistry/fluorescence in situ hybridisation discordant ALK test results

Intern Med J. 2021 Aug;51(8):1355-1356. doi: 10.1111/imj.15450.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adenocarcinoma* / drug therapy
  • Adenocarcinoma* / genetics
  • Anaplastic Lymphoma Kinase / genetics
  • Humans
  • Immunohistochemistry
  • In Situ Hybridization, Fluorescence
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / genetics
  • Neoplasms, Unknown Primary*

Substances

  • Anaplastic Lymphoma Kinase